KEY WORDS: risk factors, meconium aspiration
Fatal meconium aspiration
syndrome occurring despite airway management considered appropriate.
Neonatal morbidity included hyaline membrane disease, bronchopulmonary dysplasia, severe intraventricular hemorrhage (Grade 3 or 4), severe retinopathy (Stage 3 or 4), meconium aspiration
syndrome, pulmonary hemorrhage and perinatal mortality.
An autopsy revealed that the cause of death was cardiac arrest as a result of meconium aspiration
syndrome and bilateral pneumothoraces.
He was suffering from a clogging of the lungs after he had a bowel movement in the womb - a condition known as Meconium Aspiration
There is a much higher incidence of meconium staining, premature aspiration of meconium (in utero), meconium aspiration
syndrome, and more reports of "failure to thrive" babies.
In Nadine Wong's opinion, the company is on target to get Surfaxin approved by the FDA, as they recently completed two Phase III clinical trials of Surfaxin for the treatment of respiratory distress syndrome (RDS) in premature infants, are currently evaluating Surfaxin in a Phase III and a Phase II clinical trial for meconium aspiration
syndrome in full-term infants, and a Phase II clinical trial for acute RDS in adults.
The doctors diagnosed the baby of meconium aspiration
syndrome without evidence to support their conclusion, such as meconium staining of amniotic fluid.
But following an emergency caesarean section, the baby died of meconium aspiration
syndrome - a respiratory disorder.
Concerns that delaying elective deliveries might increase morbidity were allayed by follow-up data showing significant declines in the rates of postpartum anemia, meconium aspiration
, Apgar scores less than 5 at 1 minute, and cesarean deliveries due to fetal distress in infants delivered at 39-41 weeks' gestation in the period after the program was started, compared with the preprogram era.
Nonhomogeneous lung disease (meconium aspiration
with air trapping; meconium aspiration
, diffusely hazy; and focal pneumonia)
Surfaxin, Discovery's lead product, is currently in two pivotal Phase 3 multi-national trials for Respiratory Distress Syndrome (RDS) in premature infants, a Phase 3 clinical trial for Meconium Aspiration
(MAS) in full-term infants, and a Phase 2 clinical trial for Acute Respiratory Distress Syndrome (ARDS) in adults.